| Name | Title | Contact Details |
|---|
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.
IMGENEX is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.
Panomics is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amylin Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.